Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

759
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
759
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

685
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
685
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

650
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
650
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

950
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
950
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

643
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
643
T Cell Types and Functions01:24

T Cell Types and Functions

3.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

General phenomenon and communication experience of physician and nurse in night shift communication: A qualitative study.

Journal of nursing management·2020
Same author

LncRNA FOXP4-AS1 Is Involved in Cervical Cancer Progression via Regulating miR-136-5p/CBX4 Axis.

OncoTargets and therapy·2020
Same author

Two-generation reproduction and limited teratology studies of ethanamizuril fed to rats.

Birth defects research·2020
Same author

Epigenomic Regulatory Mechanism in Vegetative Phase Transition of <i>Malus hupehensis</i>.

Journal of agricultural and food chemistry·2020
Same author

Luteal blood flow as a predictive factor for methotrexate treatment outcomes in women with unruptured tubal pregnancy.

BMC pregnancy and childbirth·2020
Same author

Association between mean corpuscular volume and severity of coronary artery disease in the Northern Chinese population: a cross-sectional study.

The Journal of international medical research·2020
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.4K

Redefining Initial Rheumatoid Arthritis Treatment: Tofacitinib Outperforms Methotrexate in Disease Control-An

Juan Zhao1, Yu Wang1, Xuerong Deng1

  • 1Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China.

Mayo Clinic Proceedings
|April 3, 2026
PubMed
Summary
This summary is machine-generated.

Tofacitinib (TOFA) monotherapy demonstrated superior early efficacy and cost-effectiveness compared to methotrexate (MTX) with glucocorticoid bridging in rheumatoid arthritis (RA) patients. Safety profiles were comparable, supporting TOFA as a potential first-line treatment option.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K

Related Experiment Videos

Last Updated: Apr 5, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.4K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K

Area of Science:

  • Rheumatology
  • Clinical Pharmacology
  • Health Economics

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease requiring effective disease-modifying antirheumatic drugs (DMARDs).
  • Early and effective treatment is crucial to prevent joint damage and disability in RA patients.
  • Methotrexate (MTX) is a common first-line therapy, but alternatives are sought for improved efficacy and patient outcomes.

Purpose of the Study:

  • To compare the efficacy, safety, and cost-effectiveness of tofacitinib (TOFA) monotherapy against methotrexate (MTX) with glucocorticoid bridging.
  • To evaluate TOFA as a potential first-line treatment for disease-modifying antirheumatic drugs (DMARDs)-naïve rheumatoid arthritis (RA) patients.
  • To assess early clinical improvement and disease activity scores in RA patients treated with TOFA versus MTX.

Main Methods:

  • An open-label randomized controlled trial involving 116 DMARDs-naïve RA patients with moderate-to-high disease activity.
  • Patients were randomized 1:1 to receive either tofacitinib (5 mg twice daily) or methotrexate (10-20 mg weekly) with a single intramuscular betamethasone injection.
  • The primary endpoint was clinical improvement at 3 months, defined by >50% reduction in Simplified Disease Activity Index (SDAI) or an absolute SDAI decrease of ≥10.

Main Results:

  • Tofacitinib monotherapy achieved significantly higher clinical improvement rates at 3 months (94.1%) compared to methotrexate with glucocorticoid bridging (75%, P=.02).
  • The TOFA group showed significantly greater reductions in all assessed disease activity scores (SDAI, CDAI, DAS28-CRP, DAS28-ESR) at month 3.
  • Safety profiles were similar between the groups, and tofacitinib demonstrated superior cost-effectiveness.

Conclusions:

  • Tofacitinib monotherapy offers superior early efficacy compared to methotrexate plus glucocorticoid bridging in DMARDs-naïve RA patients.
  • TOFA presents a comparable safety profile and better cost-effectiveness, positioning it as a viable first-line treatment option.
  • These findings support the consideration of tofacitinib as an initial therapeutic strategy for rheumatoid arthritis.